SAA和前列腺癌病理分级和临床分期的关系_陈维真.pdfVIP

当代医学　2010年9月第16卷第25期总第216期　Contemporary Medicine, Sep. 2010,Vol.16 No.25 Issue No.216 doi:10.3969/j.issn.1009-4393.2010.25.010 SAA与前列腺癌病理分级和临床分期的关系 陈维真 张勇 罗辉 [摘要] 目的 评估前列腺癌患者血清淀粉样蛋白A(serum amyloid A，SAA)在前列腺癌不同病理分化和临床分期中表达的差异。方法 纳入前列 腺癌患者48例，前列腺增生患者32例，测定SAA水平，并将前列腺癌患者的SAA水平与肿瘤病理分化和临床分期结果进行对比分析。结果 前列腺癌 和良性前列腺增生患者的SAA水平的差异有统计学意义( 0.01)，随着肿瘤分化的降低和分期的增加，SAA水平逐渐增高。结论 SAA在前列腺癌患 P 者中的表达明显增高，可作为前列腺癌分化、分期和预后评估的重要指标。 [关键词] 前列腺癌；血清淀粉样蛋白A；病理分级；临床分期 [Abstract] Objective To evaluate the relationship between serum amyloid A protein (SAA) and tumor pathological grading and clinical staging in prostate cancer. Methods The levels of SAA were measured in 48 patients with prostate cancer and 32 patients with prostate hyperplasia. The relationship between SAA levels and tumor grading and staging were also analyzed. Results There was signifi cant difference of SAA levels between prostate cancer and prostate hyperplasia (P0.01). The SAA levels increased as the tumor pathological grading decreased and the clinical staging increased. Conclusion The SAA levels increased signifi cantly in prostate cancer patients, and could be applied as the biomarker of prostate cancer pathological grading, clinical staging and prognosis. [Key Words] Prostate cancer; serum amyloid A; Pathological grading; Clinical staging 前列腺癌是威胁全世界老年男性健康的主要恶性肿瘤之一。 mg/L，32例良性前列腺增生患者的SAA水平为(2.95±1.78)mg/L，两 论 前列腺特异抗原(prostate specific antigen，PSA)作为前列腺癌的 组患者的SAA水平差异有统计学意义( 0.01)。 P 筛选指标得到了广泛应用，但其在诊断中的敏感性、特异性却不能 2.2 血清SAA表达与